Floatz logo

ad1208

Solid Tumors Refractory to Standard Therapy

Avelos Therapeutics Inc.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

180 Active assets in the Solid Tumors Refractory to Standard Therapy cohort.

Asset / SponsorPhaseRating
Catequentinib
Nanfang Hospital, Southern Medical University
Phase 3BB
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Durvalumab
OHSU Knight Cancer Institute
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Catequentinib
First Affiliated Hospital of Wannan Medical College
Phase 3BB

View all 50 →

Same molecule, other indications

ad1208 is also rated in:

Solid Tumor, Unspecified, AdultDormant
CCC
Indicative ·
48 / 100
View asset →
Solid Tumor in Advanced StageDormant
CCC
Indicative ·
48 / 100
View asset →
neoplasmDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →